Acrux Limited (AU:ACR)
ASX:ACR
Top Page
Acrux
(Sydney:ACR)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
▼(-45.00% Downside)
Action:ReiteratedDate:11/28/25
Acrux's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and high leverage. Technical analysis provides mixed signals, with no strong momentum. Valuation metrics are concerning, with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with significant challenges ahead.
Positive Factors
Licensing / Royalty Model
Acrux's core model of licensing, royalties and milestone payments leverages partner commercial infrastructure, reducing the need for a large sales force and enabling scalable, high-margin revenue streams tied to partner product success. This model provides durable cash inflows if partners maintain launches and sales.
Negative Factors
High Leverage
A debt-to-equity ratio this elevated materially constrains financial flexibility, increasing refinancing and interest-rate risk. Over the coming months, high leverage could limit the company's ability to fund development milestones, react to partner delays, or absorb operating shortfalls without dilutive financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Licensing / Royalty Model
Acrux's core model of licensing, royalties and milestone payments leverages partner commercial infrastructure, reducing the need for a large sales force and enabling scalable, high-margin revenue streams tied to partner product success. This model provides durable cash inflows if partners maintain launches and sales.
Read all positive factors
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.52M
Dividend YieldN/A
Average Volume (3M)120.95K
Price to Earnings (P/E)9.3
Beta (1Y)0.22
Revenue Growth-76.63%
EPS Growth12.00%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acrux Business Overview & Revenue Model
Company Description
Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sec...
How the Company Makes Money
Acrux has historically generated revenue primarily through (1) royalties on net sales of products commercialized by partners that use Acrux-developed formulations and/or intellectual property, (2) upfront payments and milestone payments under lice...
Acrux Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.19M | 5.09M | 8.43M | 1.72M | 1.34M |
| Gross Profit | 1.19M | 1.13M | 1.95M | -4.65M | -7.59M |
| EBITDA | -5.17M | -8.06M | -2.79M | -12.29M | -15.59M |
| Net Income | -5.95M | -5.80M | -764.00K | -9.83M | -12.63M |
Balance Sheet | |||||
| Total Assets | 7.22M | 8.96M | 14.30M | 15.27M | 24.20M |
| Cash, Cash Equivalents and Short-Term Investments | 863.00K | 2.94M | 6.23M | 5.83M | 15.27M |
| Total Debt | 3.63M | 3.70M | 2.35M | 2.08M | 2.23M |
| Total Liabilities | 6.20M | 5.69M | 5.60M | 6.18M | 5.73M |
| Stockholders Equity | 1.02M | 3.28M | 8.70M | 9.09M | 18.47M |
Cash Flow | |||||
| Free Cash Flow | -5.48M | -4.58M | 584.00K | -9.28M | -11.52M |
| Operating Cash Flow | -5.47M | -4.30M | 703.00K | -8.82M | -11.41M |
| Investing Cash Flow | -5.00K | -276.00K | -119.00K | -465.00K | -102.00K |
| Financing Cash Flow | 3.39M | 1.29M | -183.00K | -155.00K | 17.58M |
Acrux Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
36.07
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.07 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACR.
Acrux Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$467.87M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
53 Neutral | AU$88.72M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$212.57M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
45 Neutral | AU$9.67M | -2.68 | -29.91% | ― | 178.06% | -2.49% | |
42 Neutral | AU$4.52M | 9.33 | -211.88% | ― | -76.63% | 12.00% | |
42 Neutral | AU$9.43M | -1.00 | -218.76% | ― | ― | ― |
* Healthcare Sector Average
AU:ACR
Acrux
0.01
-0.01
-56.00%
AU:CUV
Clinuvel Pharmaceuticals
9.32
-0.70
-7.00%
AU:SPL
Starpharma Holdings Limited
0.51
0.41
426.04%
AU:TRP
Tissue Repair Ltd
0.16
-0.08
-33.33%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.31
-88.57%
Acrux Corporate Events
Acrux Secures $0.55m Advance on FY26 R&D Tax Incentive to Support HRT Development
Mar 11, 2026
Acrux Limited has secured a second advance of $0.55 million against its FY26 RD Tax Incentive from Radium Capital, covering eligible RD conducted between 1 October 2025 and 28 February 2026. The funding represents about 80% of the estimated rebate...
Acrux Performance Rights Lapse After Reaching Expiry
Feb 26, 2026
Acrux Limited has notified the market that 910,769 performance rights, trading under the ASX security code ACRAT, have lapsed. The cessation follows the expiry of these rights without being exercised or converted, resulting in a reduction of the c...
Acrux Posts Strong Half-Year Profit Rebound Despite Lower Asset Backing
Feb 25, 2026
Acrux Limited reported a strong improvement in financial performance for the half-year ended 31 December 2025, with revenues from ordinary activities rising 109% to A$3.57 million. Net profit attributable to members also more than doubled to A$165...
Acrux Lifts Cash and Revenue as It Refocuses Portfolio on Higher-Value Therapies
Jan 28, 2026
Acrux reported a solid December 2025 quarter, with customer receipts rising to $1.807 million and cash and cash equivalents increasing to $0.946 million, supported by strong growth in profit-share and royalty income as its U.S. topical generics po...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.